Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to convert Phenylalanine (Phe) into Tyrosine (Tyr). PKU patients have specific dietary needs and must follow a restrictive diet in the aim of preventing toxic levels of the amino acid phenylalanine (Phe) accumulation.
The exploratory study's main objective is to measure blood amino acid levels and to gain quantitative insights in children with PKU on a protein substitute with respect to evaluation of nutritional intake.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Children with PKU | |||
| Age- and sex-matched non-PKU comparison subjects |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Amino acid levels in blood | Measuring amino acid levels in blood [μmol/L] | day 1 |
| Nutrient Intake | Measured by three-day diet diary. Nutrients in [mg/day] | day 1 - day 3 |
Not provided
Not provided
Inclusion Criteria:
Both PKU and Non-PKU comparison subjects:
Age ≥ 2 and ≤ 12 years
Willing and able to provide informed consent by parents or legal representatives (and assent if required by local law/regulations)
One subject per family
PKU subjects specific inclusion criteria:
PKU subjects identified by newborn screening and started low Phe diet before 1 month age
Usage of at least two Phe-free protein substitutes on a daily basis for at least 26 consecutive weeks up to Visit 1
Average Phe-level ≤360 µmol/L based on at least two blood Phe values from the past 12 months up to Visit 1
Non-PKU comparison subjects specific inclusion criteria:
Same age (±3 years) and sex as an included PKU subject
Exclusion Criteria:
Both PKU and Non-PKU comparison subjects:
Current psychiatric disorders
Severe hepatic, thyroid or renal dysfunction
Acute illnesses like fever, flu, diarrhea, or vomiting (subjects should be symptom free for a week prior to V1)
Serious conditions (e.g. cancer, hydrocephalus, fatal heart disease)
Participation in any other clinical intervention studies involving test products concomitantly or within six weeks prior to entry into the study
PKU specific exclusion criteria:
Use of BH4, or drugs that may interfere with main outcomes
Non-PKU comparison subjects specific exclusion criteria:
PKU diagnosis or any other diagnosed disorder of amino or organic acid metabolism
Not provided
Not provided
Not provided
Children with PKU and age- and sex-matched non-PKU comparison subjects.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dr. P. Verloo | UZ Gent, Belgium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. P. Verloo | Ghent | Belgium | ||||
| Birmingham Children's Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010661 | Phenylketonurias |
| ID | Term |
|---|---|
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| Birmingham |
| United Kingdom |
| D009422 | Nervous System Diseases |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |